Abstract
Despite a decade of immunotherapy, treatment selection in non-small cell lung cancer (NSCLC) still relies on subgroup analyses and clinical scores. I3LUNG (NCT05537922) is currently the largest international, real-world, multimodal, artificial intelligence (AI)-based trial, enrolling 2365 patients. We integrated real-world clinical data (RWD), computed tomography (CT) images, digital pathology (DP), and genomics (G) into machine learning early-fusion (MLEF) and deep-learning intermediate-fusion (DLIF) models. MLEF achieved consistent performance across outcomes (AUC≈0.74), with improved results in first-line patients (AUC up to 0.82). Multimodal models outperformed RWD in clinical-specific subgroups (AUCs up to 0.86). In the test set, AI models surpassed PD-L1, ECOG PS, NLR, LDH (all with p<0.01) and the LIPI score. The clinical usability study showed that expert and non-expert physicians could improve their prediction with the explainable AI (XAI) tool. The I3LUNG tool emerges as a clinically relevant decision-support system and is currently under prospective validation in >2,000 patients.
Competing Interest Statement
AP: Financial Interests Amgen (Advisory Board, Personal), ASTRAZENECA (Advisory Board, Other, invited SPeaker Personal), Bayer (Advisory Board, Personal), BMS (Advisory Board, Personal), Daiichii Sankyo (Invited Speaker, Personal), Gilead (Invited Speaker, Personal), IQUVIA (Invited Speaker, Personal), Italfarma (Other, Personal, Training of personnel), JANSSEN (Advisory Board, Other Personal, travel Grant), Lilly (Invited Speaker, Personal), MEDSIR (Invited Speaker, Personal), MSD (Advisory Board, Personal), Novartis (Invited Speaker, Personal), Pfizer (Advisory Board, Invited Speaker, Personal), Roche (Invited Speaker, Personal, THE HIVE PROJECT: Discussant), ASTRAZENECA (Coordinating PI, Institutional, Financial interest), BAYER (Local PI, Institutional, Financial interest), BMS (Local PI, Institutional, Financial interest), LILLY (Local PI, Institutional, Financial interest), MSD (Local PI, Institutional, Financial interest), Roche (Local PI, Institutional, Financial interest), SPECTRUM (Coordinating PI, Institutional, Financial interest); VM: Invited speaker for Novartis, and Daiichi Sankyo; AF: Novartis (Invited facilitator to AI workshop); LP: Novartis, MSD, Pfizer (Invited Speaker); MF: Novartis: Invited facilitator to AI workshop; AZ: Novartis: Invited facilitator to AI workshop; AS: Novartis, MSD, BMS, Pierre Fabbre, Immnunocore (Educational speaker); LM: Sanofi, Daiichi Sankyo, LEOPharma (Conference grants), Novartis, MSD, Elma Research (Honoraria); GC: Amgen, Astra Zeneca (Travel grant), Takeda (Honoraria and consultancy); CB: bbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb International, Catalyst, Daiichii Sankyo, EMD Serono, Genentech, Personal Gilead, Guardant,Jazz Pharmaceuticals, Johnson and Johnson, Lilly, Mirati Therapeutics, Novartis, Pfizer, Tempus, Turning Point Therapeutics, (Advisory Board, Personal), AstraZeneca, (Coordinating PI, Institutional, Financial interest, Steering Committee Member, Personal), Bristol Myers Squibb International (Other, Institutional, Financial interest, SubI on BMS funded IIT); EF: Amgen, Daiichi Sankyo (Advisory role), Pfizer, AstraZeneca, Genesis, Daiichi Sankyo, KAM (travel grants), Genesis, Lilly, GSK, AstraZeneca (speaker), Genprex Inc., Deciphera Pharmaceuticals, Inc (stock ownership); MFP: fulltime employee at MEDSIR; JRM: fulltime employee at MEDSIR; MO: Astra Zeneca, BMS, MSD (Honorary), .Astra Zeneca, BMS, MSD, Pfizer, Johnson & Johnson (Advisory Role or Conusltancy), Eli Lilly, Johnson & Johnson (Travle, Accommodation, Expenses), MB: J&J and Leopharma (Travel, accommodation and grant), BMS and AstraZeneca (honorary); TB: MSD, Sanofi, Pfizer and Lilly (Travel, accommodation and grant), MSD (honorary); CP: AstraZeneca, Roche, MSD, Bristol Myers Squibb, J&J (Hononary), AstraZeneca, Roche, MSD, J&J, Daiichi-Sankyo (Travel Accomodation), AstraZeneca, Roche, MSD, J&J, Sanofi, Takeda, Pfizer, Bristol Myers Squibb (Advisory Board, Travel accommodation), J&J, Pfizer, Eli Lilly, Spectrum Pharmaceuticals, Roche, MSD, BMS, AstraZeneca, Daiichi-Sankyo, Amgen (Principal Investigator in clinical trials); ER: ESMO; GP: Lilly, AstraZeneca, Menarini Stemline, Illumina, Roche, ADS Biotec (Honorary, travel, advisory board); FDB: Pierre Fabre, Mattioli 1885, McCann health, MSD, IQVIA, Novartis, Indena, Incyte, Taiho, Menarini, Roche (Consulting), Sanofi, BMS, Taiho, Incyte (Advisory) AnHeart Therapeutics, Apollomics, AztraZeneca, Basilea Pharmaceutica, Bayer Healthcare, Boehringer Ingelheim, BMS, F. Hoffmann-La Roche, Incyte, Itanet, Janssen-Cilag, Kymab, Loxo Oncology, MedImmune, Merck KGaA, Novartis, Tesaro, Zymeworks (PI), Nadirex, ESO, Dephaforum, Ambrosetti, Motore Sanita, Effeti, Events, Fare Comunicazione, Itanet, Nadirex, BMS, Accmed, Idea-z, Dynamicom Education, Sanofi, AstraZeneca (Speakers fee), Incyte, BMS, Novartis, Sanofi, AstraZeneca (Traveling expenses), EF: AbbVie, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, F. Hoffmann La Roche, Genentech, Genmab, Gilead, Glaxo Smith Kline, Iteos, Janssen, Johnson & Johnson, Medical Trends, Medscape, Merck Serono, Merck Sharp & Dohme LLC, Novartis, PeerVoice, Pierre Fabre, Pfizer, Regeneron (Honoraria and/or consulting fees), Grifols (independent board member, AstraZeneca, Johnson & Johnson, Roche (Support for meeting attendance and/or travel); NP: AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Imagine, Gaurdant360, Imagene, Merck, MSD, Novartis, Pfizer, Roche, Renium; Takeda (Advisory, Honorary, Research); AP: ThermoFisher, Breakthrough Cancer, Daiichi Sankyo (Scientific Advisory Board), Abbvie, IBM (Research); Caris (Travel); HL: Astra Zeneca, Merck, Pierre Fabre (Honoraria as invited speaker), Vianex, Merck (Support for attending scientific meetings), Astra Zeneca, Merck, Pfizer, Sandoz (Advisory Board), Astra Zeneca, Abbvie, Amgen, BMS, Merck, Roche, PPD, Parexel, PRA, Qualitis, Perseus Healthcare Group S.A. (Personal and Institutional fees for clinical trials); GLR: MSD, REGENERON, ROCHE, LILLY, BMS, AMGEN, ASTRAZENECA, JOHNSON AND JOHNSON, MERCK, NOVARTIS, PIERRE FABRE, BAYER, BEIGENE, PFIZER, TAKEDA, GSK, DAIICHI,SANOFI, GILEAD (Advisory boards, consultancies, travel accommodations, speaker fees, writing fees, pi role in profit trials); FT: shares of ML Cube srl, AIOM, Accademia nazionale di medicina (Honorary); AP: Srl and AllyArm Srl.AP (Co-founder), Novartis, Accmed (Invited talks), Fondazione Cariplo, Fondazione Telethon, Fondazione Valduce, Fondazione FORST, Kayser Italia srl, Generali Wellion, Tecnobody srl, EMAC srl, Merz Therapeutics, AllyArm srl (Collaboration); MCG: Abbvie, AstraZeneca, Bayer, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, Gilead Sciences, IO Biotech, Jansenn Pharmaceuticals, Merck & Co, Mirati therapeutics, Natera, Novocure, Nuvation,Nuvalent, Pfizer, Regeneron, Revolution Medicines, Roche, Summit, Takeda (Personal finance interest), Aptitude Health, Astro, Ideology, Intellisphere, MJH holding, Oncohost, IASLC (nonpharama personal finance interest).
Funding Statement
This study was funded under the framework of the Horizon Europe.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was obtained from all the involved centers: 1 Comitato etico Fondazione IRCSS Istituto Nazionale dei Tumori (INT), Ethic Committee Code 147/22, Approved on the date 25th July 2022; 2 Ethik.Kommission Universität zu Lübeck (GHD), Ethic Committee code 2022-439, Approved on the date 17th October 2022 (clinical study); 3 Scientific Committee Metropolitan Hospital (MH), Ethic committee code 30.08.2022, Approved on the date 30th August 2022; 4 Helsinki Committee Share Zedek medical Center (SZMC), Ethic Committee code 0240-22-SZMC, Approved on the date 20 September 2022; 5 COMITÉ DE ÉTICA DE INVESTIGACIÓN CON MEDICAMENTOS Y COMISIÓN DE PROYECTOS DE INVESTIGACIÓN DEL HOSPITAL UNIVERSITARI VALL D HEBRON (VHIO), Ethic Committee code PR(AG)384/2022, Approved on the date 17 January 2023; 6 Institutional review Board University of Chicago (UoC), Ethic Committee code IRB22-1305, Approved on the date 8th September 2022
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Collaborators Paolo Ambrosini, Ghazal Farhikhteh, Sabina Sangaletti, Michele Borracino, Claudia Agosta, Chiara Bonalume, Federica Corso, Roberta Serino, Eleonora Gusmaroli, Marta De Ponti, Giuseppe Nardo, Giulia Montelatici, Alessandra Russo, Giorgia Di Liberti, Stefano Natangelo, Simone Rota, Giuseppe Leone, Miriam Fink, Chiara Giangregorio, Emilia Ambrosini, Alessandro Chiesi, Erica Pietroluongo, Francesca Piazza, Natacha Bonnet, Vivek Subbiah, Julieta Pellarolo, Jana Mandler, Nadine Heuer-Olewinski, Jana Sonnek, Milena Schmidt, Christopher Wirks, Hartmut Richter, Stefania Gkoura, Eleni Aravantinou, Ioanna Gazouli, Ilaria Priano, Laura Masfarre Pinto, Aina de Torner, Augusto Valdivia, Nuria Pardo, Gerard Romero, Mireia Soleda, Halid Kayan, Anniina Hentinen, Valter Torri.
